Advertisement

best practice onkologie

, Volume 13, Issue 4, pp 182–190 | Cite as

FLT3-Inhibitoren in der Therapie der akuten myeloischen Leukämie

Topic
  • 18 Downloads

Zusammenfassung

Die Aktivierung des FLT3-Tyrosinkinaserezeptors spielt eine entscheidende Rolle in der Pathogenese der akuten myeloischen Leukämie (AML). Seit über einem Jahrzehnt sind Medikamente in Erprobung, die diesen Rezeptor samt den nachgeschalteten onkogenen Signalwegen hemmen und somit die generell schlechte Prognose der AML verbessern sollen. Mit Midostaurin ist seit Kurzem ein Inhibitor für die Erstlinientherapie der AML mit FLT3-Mutation in Kombination mit Standardchemotherapie zugelassen. Für weitere Inhibitoren wird mit einer Zulassung für die therapierefraktäre bzw. rezidivierte AML in Kürze gerechnet. In der vorliegenden Arbeit werden die aktuellen Daten und Hintergründe zur Tyrosinkinaseinhibitortherapie bei der FLT3-mutierten AML diskutiert und zukünftige Entwicklungen präsentiert. Entscheidend für die weitere Bewertung der einzelnen Inhibitoren zur Behandlung der AML mit FLT3-Mutation ist die konsequente Erfassung und Untersuchung von Patienten im Rahmen von randomisierten Studien bzw. Registerstudien.

Schlüsselwörter

Humanes FLT3-Protein Mutation Enzyminhibitoren Antineoplastische Substanzen Midostaurin 

FLT3 inhibitors for the treatment of acute myeloid leukemia

Abstract

The activation of the FLT3 tyrosine kinase receptor plays an essential role in the pathogenesis of acute myeloid leukemia (AML). For more than a decade, drugs that inhibit this receptor and its downstream oncogenic signaling pathways have been in development. These tyrosine kinase inhibitors (TKIs) are used to improve the generally dismal prognosis of AML. Recently, midostaurin has been approved for first-line treatment of FLT3-mutated AML in combination with standard chemotherapy. Novel TKIs are in clinical development and are most likely to be approved for refractory or recurrent AML in the near future. In this review, the authors present the background and current data on TKI treatment in FLT3-mutated AML and discuss their clinical impact and future developments. Apart from clinical trial results, the consequent documentation and evaluation of clinical routine outcomes in registries is essential to define the role and significance of TKIs in the treatment of AML.

Keywords

Human FLT3 protein Mutation Enzyme inhibitors Antineoplastic agents Midostaurin 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

C. Röllig weist auf folgende Beziehungen hin: Er erhielt Forschungsförderung von Abbvie, Bayer, Celgene und Novartis sowie Honorare für Beratungsleistungen von Abbvie, Amgen, BMS, Celgene, Daiichy Sankyo, Janssen, Jazz, Novartis, Pfizer, Roche und Takeda. S. Metzelder gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio M‑T, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A (2017) Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3‑mutated acute myeloid leukemia. Cancer 123(15):2867–2874.  https://doi.org/10.1002/cncr.30680 CrossRefPubMedGoogle Scholar
  2. 2.
    Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE (2011) Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 96:62–68.  https://doi.org/10.3324/haematol.2010.030452 CrossRefPubMedGoogle Scholar
  3. 3.
    Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, Connolly C, Ballen KK, Cutler CS, Dey BR, El-Jawahri A, Nikiforow S, McAfee SL, Koreth J, DeAngelo DJ, Alyea EP, Antin JH, Spitzer TR, Stone RM, Soiffer RJ, Chen Y‑B (2016) Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 175(3):496–504.  https://doi.org/10.1111/bjh.14260 CrossRefPubMedGoogle Scholar
  4. 4.
    Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368:2059–2074.  https://doi.org/10.1056/NEJMoa1301689 CrossRefGoogle Scholar
  5. 5.
    Chen Y‑B, Li S, Lane AA, Connolly C, Del Rio C, Valles B, Curtis M, Ballen K, Cutler C, Dey BR, El-Jawahri A, Fathi AT, Ho VT, Joyce A, McAfee S, Rudek M, Rajkhowa T, Verselis S, Antin JH, Spitzer TR, Levis M, Soiffer R (2014) Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transpl 20(12):2042–2048.  https://doi.org/10.1016/j.bbmt.2014.09.007 CrossRefGoogle Scholar
  6. 6.
    Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M (2013) Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3‑internal tandem duplication status. J Clin Oncol 31:3681–3687.  https://doi.org/10.1200/JCO.2013.48.8783 CrossRefPubMedGoogle Scholar
  7. 7.
    Ding L, Ley TJ, Larson DE et al (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382):506–510.  https://doi.org/10.1038/nature10738 CrossRefPubMedGoogle Scholar
  8. 8.
    Döhner K, Thiede C, Larson RA, Prior TW, Marcucci G, Jones D et al (2017) Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study. Blood 130:abstr 467Google Scholar
  9. 9.
    de Freitas T, Marktel S, Piemontese S, Carrabba MG, Tresoldi C, Messina C, Lupo Stanghellini MT, Assanelli A, Corti C, Bernardi M, Peccatori J, Vago L, Ciceri F (2016) High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 96(6):629–636.  https://doi.org/10.1111/ejh.12647 CrossRefPubMedGoogle Scholar
  10. 10.
    Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics. A study of the AML Study Group Ulm. Blood 100(13):4372–4380.  https://doi.org/10.1182/blood-2002-05-1440 CrossRefPubMedGoogle Scholar
  11. 11.
    Grunwald MR, Levis MJ (2013) FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 97:683–694.  https://doi.org/10.1007/s12185-013-1334-8 CrossRefPubMedGoogle Scholar
  12. 12.
    Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2017) SEER Cancer Statistics Review, 1975–2014. National Cancer Institute, Bethesda (https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.)Google Scholar
  13. 13.
    Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch DC, Gale RE, Vyas P, Freeman SD, Russell N, Burnett AK, Grimwade D (2016) Assessment of minimal residual disease in standard-risk AML. N Engl J Med 374(5):422–433.  https://doi.org/10.1056/NEJMoa1507471 CrossRefPubMedGoogle Scholar
  14. 14.
    Kindler T, Lipka DB, Fischer T (2010) FLT3 as a therapeutic target in AML. Still challenging after all these years. Blood 116(24):5089–5102.  https://doi.org/10.1182/blood-2010-04-261867 CrossRefPubMedGoogle Scholar
  15. 15.
    Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia. Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 100(7):2393–2398.  https://doi.org/10.1182/blood-2002-02-0420 CrossRefPubMedGoogle Scholar
  16. 16.
    Krüger WH, Hirt C, Kiefer T, Neumann T, Busemann C, Dölken G (2012) Molecular remission of FLT3-ITD(+) positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib. Bone Marrow Transpl 47(1):137–138.  https://doi.org/10.1038/bmt.2011.7 CrossRefGoogle Scholar
  17. 17.
    Larson RA, Mandrekar SJ, Sanford BL, Laumann K, Geyer SM, Bloomfield CD, Thiede C, Prior TW, Dohner K, Marcucci G, Lo CF, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Döhner H, Stone RM (2017) An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [alliance]) for newly diagnosed acute Myeloid leukemia (AML) patients with FLT3 mutations. Blood 130:abstr 145Google Scholar
  18. 18.
    Leick MB, Levis MJ (2017) The future of targeting FLT3 activation in AML. Curr Hematol Malig Rep 12:153.  https://doi.org/10.1007/s11899-017-0381-2 CrossRefPubMedGoogle Scholar
  19. 19.
    Levis M, Small D (2003) FLT3. ITDoes matter in leukemia. Leukemia 17(9):1738–1752.  https://doi.org/10.1038/sj.leu.2403099 CrossRefPubMedGoogle Scholar
  20. 20.
    Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A (2009) Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 113:6567–6571.  https://doi.org/10.1182/blood-2009-03-208298 CrossRefPubMedGoogle Scholar
  21. 21.
    Metzelder SK, Wollmer E, Neubauer A, Burchert A (2010) Sorafenib bei rezidivierter und therapierefraktarer FLT3-ITD-positiver akuter myeloischer Leukamie: eine neue Behandlungsoption. Dtsch Med Wochenschr 135:1852–1856.  https://doi.org/10.1055/s-0030-1247870 CrossRefPubMedGoogle Scholar
  22. 22.
    Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Gotze K, Linn YC, Kroger M, Reiter A, Salih HR, Heinicke T, Stuhlmann R, Muller L, Giagounidis A, Meyer RG, Brugger W, Vohringer M, Dreger P, Mori M, Basara N, Schafer-Eckart K, Schultheis B, Baldus C, Neubauer A, Burchert A (2012) High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 26:2353–2359.  https://doi.org/10.1038/leu.2012.105 CrossRefPubMedGoogle Scholar
  23. 23.
    Metzelder SK, Schroeder T, Lübbert M, Ditschkowski M, Götze K, Scholl S, Meyer RG, Dreger P, Basara N, Fey MF, Salih HR, Finck A, Pabst T, Giagounidis A, Kobbe G, Wollmer E, Finke J, Neubauer A, Burchert A (2017) Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. Eur J Cancer 86:233–239. https://doi.org/10.1016/j.ejca .2017.09.016CrossRefPubMedGoogle Scholar
  24. 24.
    Patnaik MM (2017) Midostaurin for the treatment of acute myeloid leukemia. Future Oncol 13(21):1853–1871.  https://doi.org/10.2217/fon-2017-0160 CrossRefPubMedGoogle Scholar
  25. 25.
    Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M (2017) Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia. A multicentre, first-in-human, open-label, phase 1‑2 study. Lancet Oncol 18(8):1061–1075.  https://doi.org/10.1016/S1470-2045(17)30416-3 CrossRefPubMedGoogle Scholar
  26. 26.
    Pratz K, Cherry M, Altman JK, Cooper BW et al (2017) Preliminary results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute Myeloid leukemia (AML). Blood 130:abstr 722CrossRefGoogle Scholar
  27. 27.
    Rollig C, Serve H, Huttmann A et al (2015) Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol 16:1691–1699.  https://doi.org/10.1016/S1470-2045(15)00362-9 CrossRefPubMedGoogle Scholar
  28. 28.
    Röllig C, Brandts C, Shaid S, Hentrich M, Krämer A, Junghanß C, Schleyer E, Müller-Tidow C, Berdel WE, Ritter B, Pflüger K‑H, Kramer M, Haibach M, Ehninger G, Serve H, Krause SW (2012) Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Leuk Lymphoma 53(6):1062–1067.  https://doi.org/10.3109/10428194.2011.637210 CrossRefPubMedGoogle Scholar
  29. 29.
    Sandmaier BM, Khaled S, Oran B, Gammon G, Trone D, Frankfurt O (2018) Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol 93(2):222–231.  https://doi.org/10.1002/ajh.24959 CrossRefPubMedGoogle Scholar
  30. 30.
    Schlenk R, Döhner K, Salih H, Kündgen A, Fiedler W et al (2015) Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose Cytarabine. Blood 126:abstr 322Google Scholar
  31. 31.
    Schroeder T, Zohren F, Saure C, Bruns I, Czibere A, Safaian NN, Fenk R, Haas R, Kobbe G (2010) Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy. Acta Haematol 124(3):153–159.  https://doi.org/10.1159/000320173 CrossRefPubMedGoogle Scholar
  32. 32.
    Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer K‑A, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE (2013) Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia. Results from a randomized, placebo-controlled trial. J Clin Oncol 31(25):3110–3118.  https://doi.org/10.1200/JCO.2012.46.4990 CrossRefPubMedGoogle Scholar
  33. 33.
    Shih L‑Y, Huang C‑F, Wu J‑H, Lin T‑L, Dunn P, Wang P‑N, Kuo M‑C, Lai C‑L, Hsu H‑C (2002) Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia. A comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 100(7):2387–2392.  https://doi.org/10.1182/blood-2002-01-0195 CrossRefPubMedGoogle Scholar
  34. 34.
    Smith CC, Wang Q, Chin C‑S, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485(7397):260–263.  https://doi.org/10.1038/nature11016 CrossRefPubMedGoogle Scholar
  35. 35.
    Sorà F, Chiusolo P, Metafuni E, Bellesi S, Giammarco S, Laurenti L, Ausoni G, Zini G, Bayer AJ, Mario B, Leone G, Sica S (2011) Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. Leuk Res 35(3):422–423.  https://doi.org/10.1016/j.leukres.2010.10.025 CrossRefPubMedGoogle Scholar
  36. 36.
    Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, Witte TD, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H (2017) Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377(5):454–464.  https://doi.org/10.1056/NEJMoa1614359 CrossRefPubMedGoogle Scholar
  37. 37.
    Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia. Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99(12):4326–4335CrossRefPubMedGoogle Scholar
  38. 38.
    Tschan-Plessl A, Halter JP, Heim D, Medinger M, Passweg JR, Gerull S (2015) Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. Ann Hematol 94(11):1899–1905.  https://doi.org/10.1007/s00277-015-2461-5 CrossRefPubMedGoogle Scholar
  39. 39.
    Winkler J, Rech D, Kallert S, Rech J, Meidenbauer N, Roesler W, Mackensen A (2010) Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD. A case report. Leuk Res 34(10):e270–e272.  https://doi.org/10.1016/j.leukres.2010.04.011 CrossRefPubMedGoogle Scholar
  40. 40.
    Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114(14):2984–2992.  https://doi.org/10.1182/blood-2009-05-222034 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Innere Medizin SP Hämatologie, Onkologie und Immunologie, Universitätsklinikum Gießen und MarburgPhilipps-Universität MarburgMarburgDeutschland
  2. 2.Medizinische Klinik und Poliklinik, Universitätsklinikum Carl Gustav CarusTechnische Universität DresdenDresdenDeutschland

Personalised recommendations